Anti-ovarian IgG antibodies and their applications
By using phage display technology for screening and homologous recombination construction, highly specific anti-ovarian IgG antibodies were prepared, solving the problems of difficulty in obtaining quality control samples and large batch-to-batch differences, and achieving standardization and cost reduction in anti-ovarian antibody detection.
Patent Information
- Application Number
- CN202611538419.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-09-30
- Publication Date
- 2026-11-17
AI Technical Summary
The existing quality control materials for anti-ovarian antibody detection kits are difficult to obtain, have unstable titers between batches, and pose high biosafety risks, making it difficult to achieve standardized and large-scale production.
Rabbits were immunized with natural ovarian antigens, and rabbit monoclonal antibodies were screened using phage display technology. Homologous recombination was then performed to construct human-rabbit chimeric recombinant antibodies, which were used to prepare highly specific anti-ovarian IgG antibodies as quality control and calibrators.
This method enables the efficient preparation of anti-ovarian IgG antibodies, solving the problems of difficulty in obtaining natural positive samples and large batch-to-batch variability, improving the reliability and accuracy of test results, reducing costs and simplifying operations.
Smart Images

Figure CN123106911A_ABST
Abstract
Description
Technical Field
[0001] This application relates to the field of antibody technology, and more specifically, to an anti-ovarian IgG antibody and its application. Background Technology
[0002] In female infertility, ovarian dysfunction caused by immune factors is an important but often overlooked cause. When the body's immune tolerance mechanism is disordered, autoantibodies can be produced against various ovarian tissue antigens, such as ovarian granulosa cells, theca cells, zona pellucida, and oocytes. Among them, anti-ovarian antibodies (AoAbs) are multi-target polyclonal antibodies that target antigens in ovarian granulosa cells, oocytes, luteal cells, and stromal cells. They can cause pathological damage and functional failure of the ovaries, leading to ovarian injury and infertility.
[0003] Currently, the main methods used clinically to detect anti-ovarian antibodies include indirect immunofluorescence assay, enzyme-linked immunosorbent assay (ELISA), and Western blotting. Among these, ELISA is the most widely used due to its ease of operation and ability to be mass-produced. The performance of the test kit is highly dependent on the accompanying quality control and calibrators, which are the core elements to ensure the accuracy, repeatability, and comparability of each batch of test results. However, currently commercially available anti-ovarian antibody test kits have significant shortcomings in their quality control systems. Most quality control materials use mixed serum from healthy individuals, but the collection of high-concentration large samples is difficult due to resource constraints, batch-to-batch titers are unstable, there may be interference from other autoantibodies, and there are inherent risks related to biosafety, making it difficult to achieve standardization and large-scale production.
[0004] Therefore, establishing a method for efficiently obtaining highly specific human anti-ovarian antigen IgG antibodies and applying it to the standardized quality control and calibrator system of anti-ovarian IgG antibody detection kits is of great value for improving the clinical performance of detection reagents and the quality level of the industry.
[0005] In view of this, the present invention is hereby proposed. Summary of the Invention
[0006] This application provides an anti-ovarian IgG antibody and its application. The invention uses natural ovarian antigen as an immunogen to immunize rabbits, employs phage display technology to screen for rabbit monoclonal antibodies, and then constructs a human-rabbit chimeric recombinant antibody through homologous recombination. This antibody can specifically recognize ovarian antigen, and its titer, stability, and other performance indicators all meet the requirements. It can be used as a calibrator or quality control material in an ovarian IgG antibody diagnostic kit, solving problems such as difficulty in obtaining natural positive samples and large batch-to-batch variations.
[0007] In a first aspect, this application provides an anti-ovarian IgG antibody, comprising: (I) Its heavy chain has three CDR regions with amino acid sequences as shown in SEQ ID NO:1, 2 and 3, respectively; and (II) The three CDR regions of its light chain have amino acid sequences as shown in SEQ ID NO:4, 5 and 6, respectively; or Amino acid sequences obtained by substituting, deleting, or adding one or more amino acids to the amino acid sequences described in (III), (I), or (II), and which have the same or similar function as the amino acid sequences shown in (I) or (II); or (IV) An amino acid sequence that has at least 80% homology with the sequence described in (I), (II) or (III) and has the same or similar function as the amino acid sequence shown in (I), (II) or (III).
[0008] Preferably, the three CDR regions of the heavy chain are CDR1, CDR2, and CDR3. CDR1 region: GFSLRAHG (as shown in SEQ ID NO:1) ___CDR2 region: ITSSGST (as shown in SEQ ID NO:2) ___CDR3 region: ARDRGLVLGSYSYGMDL (as shown in SEQ ID NO:3); Preferably, the three CDR regions of the light chain are CDR1, CDR2, and CDR3. CDR1: ENVYSA (as shown in SEQ ID NO:4) ___CDR2: SAS (as shown in SEQ ID NO:5) ___CDR3: QVYSDYPLT (as shown in SEQ ID NO:6).
[0009] Preferably, the anti-ovarian IgG antibody comprises: (V) Its heavy chain variable region has the amino acid sequence shown in SEQ ID NO:7; and (VI) Its light chain variable region has an amino acid sequence as shown in SEQ ID NO:8; or Amino acid sequences obtained by substituting, deleting, or adding one or more amino acids to the amino acid sequences described in (VII), (V), or (VI), and which have the same or similar function as the amino acid sequences shown in (V) or (VI); or (VIII) amino acid sequences that are at least 80% homologous to the sequences described in (V), (VI) or (VII) and have the same or similar function as the amino acid sequences shown in (V), (VI) or (VII).
[0010] Preferably, the amino acid sequence of the heavy chain variable region is: QSLEESGGRLVTPGTPLTLTCTVSGFSLRAHGMSWVRQAPGKGLEWIGIITSSGSTYYASWAKGRFTTSKTSTTVDLKITSPTTEDTATYFCARDRGLVLGSYSYGMDLWGPGTLVTVSS (as shown in SEQ ID NO:7). Preferably, the amino acid sequence of the light chain variable region is: AIKMTQTPPSLSASVGGTVTINCLASENVYSAVAWYQQKPGKPPTLLISSASNLESGVPPRFSGSGSGTDYTLTIGGVQAEDAATYFCQVYSDYPLTFGAGTKVEIK (as shown in SEQ ID NO:8).
[0011] Secondly, the present invention provides a nucleic acid molecule encoding the above-mentioned anti-ovarian IgG antibody.
[0012] Thirdly, the present invention provides an expression vector comprising the above-mentioned nucleic acid molecule.
[0013] Preferably, the above expression vector includes any one of the following: phage display vector (for antibody library construction and surface display screening), prokaryotic soluble expression vector (for soluble expression and purification of scFv or Fab fragments), and eukaryotic / mammalian cell expression vector (for recombinant expression of complete IgG antibodies).
[0014] Preferably, in the above expression vectors, the phage display vector includes, but is not limited to, the following backbone: pComb3 series vectors: pComb3X and / or pComb3XSS; pCANTAB series vectors: pCANTAB-5E; pIT2 vectors; pAK series vectors.
[0015] Preferably, the prokaryotic soluble expression vectors mentioned above include, but are not limited to, any one of pET-22b(+), pET-28a(+), and pBAD / gIII.
[0016] Preferably, the eukaryotic / mammalian cell expression vector mentioned above includes one or more of the following: pcDNA3.1(+) derived vector, pTT5 vector, and pOptiVEC-TOPO.
[0017] Preferably, in the above expression vectors, regardless of the backbone used, the expression vector preferably contains at least one of the following elements: promoter, signal peptide sequence, screening marker, purification tag, fusion display element, and origin of replication.
[0018] Fourthly, the present invention provides a host cell for transformation and / or transfection of the above-mentioned expression vector.
[0019] Preferably, the host cell includes, but is not limited to, one or more of the following: prokaryotic host cells, eukaryotic host cells, and yeast host cells.
[0020] Preferably, the host cell is selected from Escherichia coli, including but not limited to one or more of the following strains: TG1, SS320, HB2151, BL21(DE3), BL21(DE3)pLysS, W3110, Top10 and DH5α.
[0021] Preferably, the eukaryotic host cell is selected from mammalian cells, including but not limited to one or more of HEK293, HEK293F, HEK293T, CHO-K1, CHO-S, CHO-DG44, Sp2 / 0, and NSO.
[0022] Preferably, the host cell, the yeast host cell, includes, but is not limited to: Pichia pastoris and / or Saccharomyces cerevisiae.
[0023] Fifthly, the present invention provides a conjugate comprising: obtained by chemically or biologically labeling the above-mentioned anti-ovarian IgG antibody.
[0024] Preferably, in the above-described combination, the marking method is selected from any one or a combination of the following: Chemical coupling labeling: The reporter molecule is covalently coupled to the amino, thiol, aldehyde or glycosyl sites on the antibody molecule through an active cross-linking agent; Enzymatic labeling: Using site-specific enzymatic ligation catalyzed by transglutaminase (mTGase) or glycosyltransferase, tags or reporter molecules are site-specifically linked to the Fc region or hinge region of antibodies; Biotin-avidin system labeling: Biotin is first covalently modified with antibodies via NHS-Biotin ester or Biotin-PEG-Mal, and then conjugated with a reporter molecule of streptavidin or neutral avidin to form a complex. Genetic engineering fusion labeling: The antibody coding sequence is fused with the tag peptide coding sequence to obtain a recombinant antibody fragment with its own labeled epitope (i.e., the direct use of tags such as His6, FLAG, and Myc in the aforementioned vector).
[0025] Preferably, in the above-mentioned conjugate, the chemical labeling includes the use of a chemical cross-linking agent; The bifunctional cross-linking agents used in the chemical coupling include, but are not limited to: Amino-directed crosslinking agents: glutaraldehyde, carbodiimide (EDC) / N-hydroxysuccinimide (NHS) system, sulfonyl-SMCC (Sulfo-SMCC); Thiol-based directional crosslinking agents: SPDP, SM(PEG)n series, maleimide-PEG-NHS (Mal-PEG-NHS); Glycosyl oxidative coupling reagent: Sodium periodate (NaIO4) mediated aldehyde-hydrazide linkage; Cleavable linker: A disulfide linker derived from SPDP, used for controlled dissociation after labeling.
[0026] Preferably, in the above-mentioned conjugates, the types of chemical or biological markers include: Enzyme markers: horseradish peroxidase (HRP), alkaline phosphatase (AP), β-galactosidase (β-Gal), glucose oxidase (GOD); Fluorescent / luminescent markers: FITC (fluorescein isothiocyanate), phycoerythrin (PE), allophycocyanin (APC), Alexa Fluor series dyes, Cy3 / Cy5 / Cy7 cyanine dyes, quantum dots, lanthanide chelates (Eu) 3+ / Tb 3+ ); Radioactive marker: Iodine-125 ( 125 I), Technetium-99m ( 99m Tc), Fluorine-18 ( 18 F) labeled complex precursor; Colloidal gold / nanoparticles: colloidal gold particles (5~40 nm), superparamagnetic iron oxide nanoparticles (SPIO), and silica fluorescent nanoparticles; Streptavidin preconjugates: HRP-streptavidin, fluorescent microsphere-streptavidin complex.
[0027] Preferably, in the above-mentioned combination, the combination has structural features including, but not limited to, the following forms: Antibody-enzyme direct conjugates (such as anti-ovarian IgG-HRP, anti-ovarian IgG-AP); Antibody-fluorescent dye conjugates (such as anti-ovarian IgG-FITC, anti-ovarian IgG-PE); An indirect labeling complex formed by an antibody-biotin conjugate and a streptavidin-enzyme / fluorescent complex; Antibody-gold nanoparticle conjugate for immunochromatographic gold assay strips; Antibody-magnetic bead conjugates (antibody coated on the surface of carboxyl / toluenesulfonyl modified magnetic beads) are used for the separation or detection of ovarian antigens. Antibody-quantum dot conjugates for multicolor analysis of oocyte surface antigens in flow cytometry or immunofluorescence imaging.
[0028] In a sixth aspect, the present invention provides conjugates, comprising: obtained by conjugating the above-mentioned anti-ovarian IgG antibody and / or the above-mentioned conjugates with a solid or semi-solid medium.
[0029] Preferably, the solid medium in the above coupling is selected from one or more of the following: Microplates / micromembranes: 96-well and 384-well ELISA plates made of polystyrene (PS) or polyvinyl chloride (PVC), as well as nitrocellulose membranes (NC membranes), nylon membranes, and PVDF membranes; Microspheres / particles: Carboxyl-modified polystyrene microspheres, amino microspheres, tosyl-activated microspheres, aldehyde microspheres, streptavidin-coated microspheres; Magnetic microparticles: carboxyl magnetic beads, amino magnetic beads, silanol magnetic beads, Protein A / G pre-coupled magnetic beads; Colloidal gold pad / glass fiber membrane: the substrate for the gold label pad, sample pad, and conjugate pad in immunochromatographic test strips; Chip substrates: glass wafers, silicon wafers, quartz wafers, polymer chip (PMMA / PDMS) surface and three-dimensional hydrogel-modified chips; Latex particles: polystyrene latex microspheres and fluorescent latex microspheres, used for latex aggregation or turbidimetric detection.
[0030] Preferably, the semi-solid medium in the above coupling is selected from one or more of the following: Gel media: agarose gel, polyacrylamide gel, sodium alginate gel beads; Hydrogel matrix: gelatin sponge, chitosan membrane, hyaluronic acid cross-linked hydrogel; Chromatography matrix: agarose beads (Sepharose), dextran gel (Sephadex), and activated agarose (CNBr-, NHS-activated agarose). The test strip support medium is a lateral flow chromatography strip system composed of nitrocellulose membrane strips, glass fiber mat, polyester nonwoven fabric, etc.
[0031] Preferably, the coupling forms between the antibody or conjugate and the medium in the above-mentioned conjugates include, but are not limited to: Physical adsorption coupling: Antibodies / conjugates are directly coated onto the surface of polystyrene microplates, NC membranes, and glass fiber membranes through hydrophobic interactions, electrostatic adsorption, or van der Waals forces. Chemical covalent coupling: The active groups (carboxyl, amino, hydroxyl) on the surface of the medium are covalently linked to the amino or thiol groups on the antibody via a cross-linking agent; Affinity capture conjugation (indirect fixation): The surface of the medium is pre-coated with streptavidin, Protein A, Protein G or anti-human IgG secondary antibody, and the anti-ovarian IgG antibody / conjugate is indirectly captured and fixed on the surface of the medium through biotin-avidin binding or antigen-antibody binding. In-situ crosslinking fixation: The antibody is mixed with the matrix material (such as prepolymer hydrogel) and simultaneously solidified under the action of crosslinking agents (glutaraldehyde, genipin), so that the antibody is intercalated and distributed inside the semi-solid gel network. Spatial directional coupling: Utilizing the thiol groups generated by the oxidation of glycosyl groups in the Fc fragment of the antibody (sodium periodate method) or the reduction of the Fab fragment, the antigen binding sites are specifically linked to the activated surface of the medium through site-specific coupling, keeping the antigen binding sites facing the solution phase and reducing steric hindrance.
[0032] Preferably, in the above-mentioned couplings, the couplings are structurally formed in at least one of the following specific product forms: Antibody-coated microplates / strips: solid-phase carriers used for ELISA detection of ovarian antigens; Antibody-conjugated magnetic beads: used for immunomagnetic bead separation (IMS) or homogeneous chemiluminescence / turbidimetric detection of ovarian antigens; Antibody-conjugated fluorescent microspheres / latex microspheres: used in flow cytometry, immunoturbidimetry, or latex agglutination assays; Antibody-colloidal gold / binding pad complex: used for the detection line (T line) or binding pad in immunochromatographic test strips (lateral flow immunoassay); Antibody-conjugated agarose / gel beads: used for affinity chromatography purification of ovarian antigens or solid-phase adsorption columns; Antibody-immobilized detection / control lines on NC membranes: membrane strip conjugates used in immunochromatographic test strips; Antibody-integrated hydrogel film: used for solid-phase capture and imaging analysis of ovarian surface antigens in vitro.
[0033] In a seventh aspect, the present invention provides the use of the above-mentioned anti-ovarian IgG antibody, the above-mentioned nucleic acid molecule, the above-mentioned expression vector, the above-mentioned host cell, the above-mentioned conjugate and / or the above-mentioned conjugate in any of the following: (a) Preparation of products for detecting ovarian antigens; (b) Quality control or calibrator for preparing anti-ovarian IgG antibodies.
[0034] In an eighth aspect, the present invention provides quality control products and / or calibrators, comprising: the above-mentioned anti-ovarian IgG antibody, the above-mentioned nucleic acid molecule, the above-mentioned expression vector, the above-mentioned host cell, the above-mentioned conjugate and / or the above-mentioned conjugate.
[0035] In a ninth aspect, the present invention provides a detection product comprising: the above-mentioned anti-ovarian IgG antibody, the above-mentioned nucleic acid molecule, the above-mentioned expression vector, the above-mentioned host cell, the above-mentioned conjugate, the above-mentioned conjugate and / or the above-mentioned quality control product and / or calibrator.
[0036] Preferably, the test product is selected from any one or more combinations of the following: Immunochromatographic assay products: Lateral Flow Assay (LFA): A strip or card-type product assembled from a sample pad, conjugate pad, nitrocellulose membrane (T line / C line), absorbent pad and PVC base plate; Colloidal gold immunochromatographic test strip: The conjugate pad is immobilized with the above-mentioned anti-ovarian IgG antibody-colloidal gold conjugate, and the T line is the ovarian antigen-mediator conjugate; Fluorescent microsphere chromatography strips: These are quantitative or semi-quantitative chromatography cards that use fluorescent microspheres instead of colloidal gold as signal markers and are used in conjunction with a fluorescence reader. Enzyme-linked immunosorbent assay (ELISA) products: Enzyme-linked immunosorbent assay (ELISA) kit: includes ovarian antigen-coated microplate, enzyme-labeled conjugate (HRP / AP-labeled anti-ovarian IgG antibody or secondary antibody), substrate solution (TMB / OPD or pNPP), washing solution and stop solution; Chemiluminescent immunoassay (CLIA) kit: using HRP or alkaline phosphatase labeling in combination with luminol / AMPPD substrate system, or magnetic microparticle chemiluminescence system (ovarian antigen-conjugated magnetic beads as solid phase, enzyme-labeled anti-ovarian IgG antibody as tracer). Homogeneous immunoassay products: Immunoturbidimetric / Latex-Enhanced Immunoturbidimetric Kit: Contains anti-ovarian IgG antibody-conjugated latex microspheres for homogeneous quantitative detection of ovarian antigen or anti-ovarian IgG antibody on fully automated biochemical analyzers or specific protein analyzers; Immunofluorescence homogeneous detection reagent: Based on the principle of fluorescence resonance energy transfer (FRET) or time-resolved fluorescence (TRFIA), lanthanide-labeled ovarian antigens are paired with capture antibodies for use; Flow cytometry detection products: Ovarian cell surface antigen flow cytometry detection reagent: contains fluorescently labeled anti-ovarian IgG antibody (FITC / PE / APC labeled), used for quantitative analysis of the positive rate of ovarian cell / granulosa cell surface antigen and antibody binding strength on flow cytometer; Antibody-magnetic bead sorting reagent: for immunomagnetic bead sorting (MACS) of ovarian antigen-positive cell subsets; Immune chip / microarray products: Protein chip: Ovarian antigen or anti-ovarian IgG antibody / monoclonal antibody is immobilized on the surface of a glass slide / polymer chip, and is used with a fluorescently labeled sample or enzyme-labeled secondary antibody detection system; Microfluidic immunoassay card: A microfluidic chip device that integrates sample pretreatment, antigen / antibody capture, signal amplification, and detection. Nucleic acid and cell-related testing products: Phage antibody library selection: Immobilized ovarian antigen-coated plates / magnetic beads were used to enrich anti-ovarian IgG antibody clones in the natural library constructed from the above host cells; In situ hybridization / RT-PCR auxiliary diagnostic reagents: containing the above nucleic acid molecules as probes or primer controls, used for the identification of anti-ovarian IgG antibody gene sequences; Colloidal gold / latex agglomerates: (Visually identifiable product) Slide agglutination assay reagent: Contains ovarian antigen-sensitized latex particles for rapid visual qualitative detection of anti-ovarian IgG antibodies in serum or follicular fluid; Immunogold filtration assay (DIGFA) test card: After adding the sample, directly visually inspect the colored spots.
[0037] Preferably, the detection product further includes one or more of the following auxiliary reagents: Solid supports: microporous plates, NC membrane strips, magnetic microparticle suspensions; Control standards: positive control for ovarian antigen, negative control (normal irrelevant IgG), and borderline quality control standard; Enzyme substrate systems: TMB chromogenic solution, OPD chromogenic solution, BCIP / NBT, CSPD chemiluminescent substrate; Washing buffer: PBST (PBS containing 0.05% Tween-20), TBST; Blocking solution: a buffer solution containing 1-5% BSA or skim milk powder; Sample processing solutions: serum diluent, follicular fluid pretreatment solution, and erythrocyte lysis buffer; Label diluent: pH-stable buffer system containing BSA and preservatives.
[0038] Preferably, the objects tested by the above-mentioned testing products include, but are not limited to: Ovarian granulosa cell / oocyte cell membrane surface antigens; Free ovarian-associated antigen proteins in follicular fluid / ovarian tissue; Anti-ovarian IgG antibodies in female serum, follicular fluid, cervical mucus, and peritoneal fluid; Ovarian immunological markers in clinical samples from in vitro fertilization (IVF) / assisted reproduction (ART).
[0039] In summary, this application has the following beneficial effects: 1. Using the quality control or calibrator of the present invention for reagent kit testing can reduce the cost of parallel comparisons, and the quality control parameters can be used for a long time.
[0040] 2. The quality control or calibration products of the present invention have good stability, which can reduce waste.
[0041] 3. Using the quality control or calibrators of this invention for reagent kit testing can reduce the cost of hospital testing projects.
[0042] 4. The quality control or calibration products of the present invention are relatively simple and readily available, with small batch-to-batch differences. Attached Figure Description
[0043] Figure 1 : Electrophoresis diagram of the antibody in this application. Detailed Implementation
[0044] The primary objective of this invention is to provide an anti-ovarian IgG antibody to address the problems of difficulty in obtaining natural positive serum raw materials, high cost, low yield, and large batch-to-batch variation, thereby improving the reliability and accuracy of anti-ovarian IgG antibody detection results.
[0045] A second objective of this invention is to provide a biomaterial.
[0046] A third objective of this invention is to provide a modified anti-ovarian IgG antibody.
[0047] A fourth objective of this invention is to provide the application of the above-mentioned anti-ovarian IgG antibody or biomaterial or modified anti-ovarian IgG antibody.
[0048] The fifth objective of this invention is to provide a product.
[0049] To achieve the above objectives, the following technical solution is adopted: In a first aspect, the present invention provides an anti-ovarian IgG antibody, comprising a heavy chain and a light chain; the amino acid sequence of the CDR region of the heavy chain is shown in SEQ ID NO.1 to SEQ ID NO.3; the amino acid sequence of the CDR region of the light chain is shown in SEQ ID NO.4 to SEQ ID NO.6.
[0050] Secondly, the present invention provides an anti-ovarian IgG antibody, comprising a heavy chain variable region and a light chain variable region. The amino acid sequence of the heavy chain variable region is shown in SEQ ID NO.7, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO.8.
[0051] Thirdly, the anti-ovarian IgG antibody has a variable region of rabbit Fab and a constant region of human IgG subtype.
[0052] Fourthly, the present invention provides a biomaterial selected from any one of a to c: a. Nucleotides, said nucleotides comprising a nucleotide sequence encoding the anti-ovarian IgG antibody; b. A carrier carrying the nucleotides in a; c. A cell carrying the nucleotides in a, or containing the carrier in b, or expressing the anti-ovarian IgG antibody.
[0053] Fifthly, the present invention provides a modified anti-ovarian IgG antibody, obtained by modifying the aforementioned anti-ovarian IgG antibody. As a further technical solution, the modification includes antibody engineering modification and chemical modification; the antibody engineering modification includes affinity maturation modification, subtype conversion modification, bispecific antibody modification, glycosylation modification, fusion protein modification, disulfide bond optimization modification, and surface charge optimization modification; the chemical modification includes polyethylene glycol modification, drug conjugation modification, and labeling modification.
[0054] In a sixth aspect, the present invention provides the use of anti-ovarian IgG antibodies, or biological materials, or modified anti-ovarian IgG antibodies in any of the following: (I) Preparation of products for detecting ovarian antigens; (II) Prepare quality control or calibrator samples for anti-ovarian IgG antibodies.
[0055] The present application will be further described in detail below with reference to the embodiments.
[0056] Unless otherwise specified, the raw materials used in the embodiments and comparative examples of this application are all commercially available.
[0057] Example 1: Rabbit Immunization Two rabbits were immunized with ovarian natural antigen according to the immunization protocol, with each rabbit receiving an immunization dose of 1 mg-0.5 mg-0.5 mg. Serum from the third immunization was used for titer analysis, and the results are shown in Table 1. The rabbit serum titers all reached 1 / 64kJ. Phage libraries were constructed using PBMCs.
[0058] Table 1. Detection of serum titers in three rabbits.
[0059] Example 2: Construction and screening of phage antibody library Following the instructions of commercially available kits, rabbit PBMCs were used to construct phage libraries. Ovarian antigen-coated magnetic beads were used as selectors, and the phage library underwent three rounds of enrichment screening. The reactivity of polyclonal antibodies obtained in each round was assessed to determine the enrichment status. From the phage antibody library after the third round of screening, 300 single colonies were randomly selected and analyzed using a magnetic microparticle platform via ELISA to evaluate the reactivity of the single-clonal phages. The 30 most reactive phage single clones were selected and sequenced. Based on the sequencing diversity results, three single clones were ultimately selected for recombinant construction, retaining the rabbit Fab region and replacing the Fc region with human IgG.
[0060] Example 3 Expression and purification of anti-ovarian IgG antibody Three antibodies were transfected into 293 cells using transient expression. After 6 days of culture, the cell supernatant was collected by centrifugation. The reactivity of the cell supernatant was detected using an anti-ovarian IgG antibody detection kit (magnetic microparticle chemiluminescence). Immunoaffinity purification was performed using SPA. The luminescence value detection results and antibody purification yield are shown in Table 2. The purification yield of AoAb 105 rhIgG was relatively low and will not be evaluated further.
[0061] Table 2 Reactivity of transiently transferred cell supernatant
[0062] Example 4 Antibody titer detection The three antibodies were serially diluted using PBST containing 20% fetal bovine serum. Detection was performed using an anti-ovarian IgG antibody detection kit (magnetic microparticle chemiluminescence assay). The luminescence values of the three antibodies at a 1000-fold dilution were all above 50 million, indicating that their titers met the requirements. The experimental results are shown in Table 3. However, the purification yield of AoAb 105 rhIgG was low and will not be evaluated further.
[0063] Table 3 Reactivity of transiently transferred cell supernatant
[0064] Example 5 Antibody stability test Two antibodies were diluted to 1 million, 5 million, and 10 million sera using clinically negative serum. They were then incubated at 4°C for 1 day and 3 days, at room temperature for 4 hours and 8 hours, followed by 3 and 7 freeze-thaw cycles, and at -20°C for 2 weeks and 1 month, followed by 3 and 7 freeze-thaw cycles. Reactivity was detected using an anti-ovarian IgG detection kit (magnetic microparticle chemiluminescence assay). The data are shown in Table 4. Under different accelerated conditions, the decrease in luminescence value of AoAb 033rhIgG at different dilution levels was within 10%, meeting the requirements. The analytical results are shown in Table 5.
[0065] Table 4. Luminescence values under different acceleration conditions
[0066] Table 5. Decrease in luminescence value under different acceleration conditions
[0067] In summary, the recombinant antibody of the present invention meets the requirements in terms of titer and stability, and can be used as a quality control and calibrator for anti-ovarian IgG antibody detection kits. At the same time, it can solve the problems of difficulty in obtaining natural clinical samples and difficulty in batch-to-batch control, and can reduce costs and facilitate operation.
[0068] This specific embodiment is merely an explanation of this application and is not intended to limit it. After reading this specification, those skilled in the art can make modifications to this embodiment without contributing any inventive step, but such modifications are protected by patent law as long as they fall within the scope of the claims of this application.
Claims
1. An anti-ovarian IgG antibody, characterized in that, include: (I) Its heavy chain has three CDR regions with amino acid sequences as shown in SEQ ID NO:1, 2 and 3, respectively; and (II) The three CDR regions of its light chain have amino acid sequences as shown in SEQ ID NO:4, 5 and 6, respectively; or Amino acid sequences obtained by substituting, deleting, or adding one or more amino acids to the amino acid sequences described in (III), (I), or (II), and which have the same or similar function as the amino acid sequences shown in (I) or (II); or (IV) An amino acid sequence that has at least 80% homology with the sequence described in (I), (II) or (III) and has the same or similar function as the amino acid sequence shown in (I), (II) or (III).
2. The anti-ovarian IgG antibody as described in claim 1, characterized in that, (V) Its heavy chain variable region has the amino acid sequence shown in SEQ ID NO:7; and (VI) Its light chain variable region has an amino acid sequence as shown in SEQ ID NO:8; or Amino acid sequences obtained by substituting, deleting, or adding one or more amino acids to the amino acid sequences described in (VII), (V), or (VI), and which have the same or similar function as the amino acid sequences shown in (V) or (VI); or (VIII) amino acid sequences that are at least 80% homologous to the sequences described in (V), (VI) or (VII) and have the same or similar function as the amino acid sequences shown in (V), (VI) or (VII).
3. A nucleic acid molecule encoding the anti-ovarian IgG antibody as described in claim 1 or 2.
4. An expression carrier, characterized in that, include: The nucleic acid molecule as described in claim 3.
5. A host cell, characterized in that, Transformation and / or transfection of the expression vector as described in claim 4.
6. The composite, characterized in that, include: The labeled anti-ovarian IgG antibody according to claim 1 or 2.
7. A coupling, characterized in that, include: The anti-ovarian IgG antibody as described in claim 1 or 2 and / or the conjugate as described in claim 6 with a solid or semi-solid medium.
8. The use of the anti-ovarian IgG antibody as described in claim 1 or 2, the nucleic acid molecule as described in claim 3, the expression vector as described in claim 4, the host cell as described in claim 5, the conjugate as described in claim 6, and / or the conjugate as described in claim 7 in any of the following: (a) Preparation of products for detecting ovarian antigens; (b) Quality control or calibrator for preparing anti-ovarian IgG antibodies.
9. Quality control products and / or calibrators, characterized in that, include: The anti-ovarian IgG antibody as described in claim 1 or 2, the nucleic acid molecule as described in claim 3, the expression vector as described in claim 4, the host cell as described in claim 5, the conjugate as described in claim 6, and / or the conjugate as described in claim 7.
10. The product being tested, characterized in that, include: (a) The anti-ovarian IgG antibody as described in claim 1 or 2; and / or (b) The nucleic acid molecule as described in claim 3; and / or (c) The expression vector as described in claim 4; and / or (d) The host cell as described in claim 5; and / or (e) the combination as described in claim 6; and / or (f) The coupling as described in claim 7; and / or (g) The quality control products and / or calibrators as described in claim 9.
